PPAR-gamma agonists and diabetic nephropathy.
Diabetic nephropathy is a clinical syndrome of albuminuria, declining glomerular filtration rate, and increased risk of cardiovascular disease. Multiple mechanisms have been implicated in its pathogenesis. Although current therapies appear to be effective, treatment of diabetic nephropathy remains suboptimal. This review summarizes the recently emerging evidence suggesting that peroxisome proliferator-activated receptor-gamma agonists may prove to be effective therapeutic agents in the treatment of diabetic renal complications.
Zhang
Yahua
Y
Division of Nephrology and Hypertension, S-3223 MCN, Vanderbilt University Medical Center, Nashville, TN 37232-2372, USA.
Guan
Youfei
Y
D000818:Animals; D003928:Diabetic Nephropathies / Q000378:metabolism / Q000517:prevention & control*; D018450:Disease Progression; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D047495:PPAR gamma / Q000819:agonists*; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones